Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Transcode Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 16 | 13 | −3 |
| Shares | 2.35M | 1.09M | −1.26M (−53.7%) |
| Value | $5.98M | $3.14M | −$2.84M (−47.5%) |
New holders (0)
Institutions that held Transcode Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
None.
Sold out (3)
Institutions that held Transcode Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| AIGH Capital Management LLC | 1,270,600 | $3.23M |
| High Net Worth Advisory Group LLC | 2,500 | $6.00K |
| Royal Bank of Canada | 49 | $0 |